Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders for Galectin Therapeutics Inc., held on December 3, 2025. The filing details the election of directors, executive compensation advisory votes, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: All 11 nominated directors were elected. Votes ranged from approximately 25.3 million to 25.9 million "For" votes, with broker non-votes totaling 19,513,532 for each nominee.
- Executive Compensation (Say-on-Pay): Stockholders approved the non-binding advisory resolution to approve executive compensation with 25,260,489 votes "For" and 639,415 votes "Against."
- Frequency of Say-on-Pay Votes: Stockholders recommended conducting advisory votes on executive compensation every three years (22,075,944 votes for 3 years vs. 3,616,823 for 1 year).
- Auditor Ratification: Stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2025, with 45,458,024 votes "For."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the tenure of the newly elected directors and any changes to board composition.
- Review the proxy statement for details on the specific executive compensation packages approved.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2025, as this 8-K does not contain financial data.